The only way for it to not cause any adverse effects is for it to be delivered to the cancer and not the whole body. That is the whole point of targeted delivery. At the moment the drug goes through the whole body and is diluted, but by targeting it there is no waste. I am only pointing out what the plan from Starpharma has been from the start. I don't know if that has been achieved, or has it? Having said that it is still a good thing that has been done if they have removed the solvent part for now. But we don't know?
Ann: DEP Docetaxel Trial Dose Exceeds Common Taxotere Dose Level, page-13
Add SPL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
10.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $43.90M | |||
| Open | High | Low | Value | Volume |
| 10.5¢ | 11.5¢ | 10.0¢ | $110.6K | 1.006M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 83046 | 10.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 11.0¢ | 30000 | 1 |
View Market Depth
| Last trade - 16.10pm 15/11/2024 (20 minute delay) ? |
| SPL (ASX) Chart |